Quick Answer
Probiotics has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: In this scoping review, the evidence on the role of Lactobacillus- and Bifidobacterium-based probiotic supplementation in managing GDM is mapped systematically, and knowledge gaps and future research directions are identified.
Key Takeaways
- 01In this scoping review, the evidence on the role of Lactobacillus- and Bifidobacterium-based probiotic supplementation in managing GDM is mapped systematically, and knowledge gaps and future research directions are identified. [Uzair SA (2026)]
- 02The findings consistently showed improvements in fasting glucose levels, insulin sensitivity, and reduction in serum insulin levels and homeostatic model assessment for insulin resistance with increased Quantitative Insulin Sensitivity Check Index scores. [Uzair SA (2026)]
- 03The evidence indicates the potential of Lactobacillus- and Bifidobacterium-based probiotic interventions to beneficially influence glucose metabolism, inflammatory response, and gut microbial balance in GDM. [Uzair SA (2026)]
- 04Gestational diabetes mellitus (GDM) affects 14% of pregnancies globally, contributing to gut microbial dysbiosis, inflammation, and insulin resistance. [Uzair SA (2026)]
The current Migaku evidence database contains 2 reusable source documents for Probiotics. This answer focuses on safety, limits, and clinician-discussion contexts.
- In this scoping review, the evidence on the role of Lactobacillus- and Bifidobacterium-based probiotic supplementation in managing GDM is mapped systematically, and knowledge gaps and future research directions are identified. [Uzair SA (2026); evidence level 3]
- The findings consistently showed improvements in fasting glucose levels, insulin sensitivity, and reduction in serum insulin levels and homeostatic model assessment for insulin resistance with increased Quantitative Insulin Sensitivity Check Index scores. [Uzair SA (2026); evidence level 3]
- The evidence indicates the potential of Lactobacillus- and Bifidobacterium-based probiotic interventions to beneficially influence glucose metabolism, inflammatory response, and gut microbial balance in GDM. [Uzair SA (2026); evidence level 3]
- Gestational diabetes mellitus (GDM) affects 14% of pregnancies globally, contributing to gut microbial dysbiosis, inflammation, and insulin resistance. [Uzair SA (2026); evidence level 3]
- Gut microbiota, immune parameters and, in turn, psoriasis symptom improvement have recently been associated with the use of probiotics in several different studies. [Ayuningtyas M (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources